Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06017622 · ClinicalTrials.gov registry record
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
A clinical trial of Acute Cannabis-induced CNS Depression, sponsored by Anebulo Pharmaceuticals.
- Recruiting
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT06017622: Recruiting study of Acute Cannabis-induced CNS Depression, sponsored by Anebulo Pharmaceuticals.
NCT06017622 is a study of Acute Cannabis-induced CNS Depression that is actively recruiting participants, run by Anebulo Pharmaceuticals. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06017622, a study of Acute Cannabis-induced CNS Depression, is actively recruiting participants, sponsored by Anebulo Pharmaceuticals.
- RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to acute cannabis-induced CNS depression.
Conditions Studied
Study Locations (1)
Massachusetts
- University of Massachusetts Memorial Children's Medical Center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2026-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06017622
The ClinicalTrials.gov registry entry for NCT06017622 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anebulo Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Cannabis-induced CNS Depression appearing as the primary indexed condition, and to 0 interventions.
NCT06017622 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06017622 about?
NCT06017622 is a clinical study titled "Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression". This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to acute cannabis-induced CNS depression.
What is the current status of trial NCT06017622?
This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2023-06-01. Estimated completion is 2026-12-30.
What conditions does trial NCT06017622 study?
This clinical trial studies the following conditions: Acute Cannabis-induced CNS Depression.
Who is sponsoring clinical trial NCT06017622?
This trial is sponsored by Anebulo Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06017622 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.